Core Insights - Sarepta Therapeutics (SRPT) has sold at least $174 million worth of its equity investment in Arrowhead Pharmaceuticals to fund a $100 million milestone payment related to the phase I/II study of SRP-1003 for treating myotonic dystrophy type 1 (DM1) [1][4][5] - Following the announcement, Sarepta's shares rose approximately 9%, although the stock has declined 83.2% year-to-date compared to a 2% decline in the industry [1][4] Company Developments - Sarepta entered an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals in February 2025, acquiring rights to four investigational RNA interference therapeutics [3] - The decision to sell equity in Arrowhead was driven by a milestone payment obligation due to the successful early enrollment and safety review of SRP-1003 [4][6] - Sarepta has sold 9.26 million shares of Arrowhead in a private sale and expects to receive at least $174 million in cash proceeds [5] Financial and Operational Challenges - The company is facing scrutiny from investors due to three patient deaths linked to its gene therapy treatments, which were attributed to acute liver failure [6][7] - Following these incidents, Sarepta suspended dosing of Elevidys for non-ambulatory patients but has since resumed shipments after FDA clearance for ambulatory patients [8][9] - To address safety concerns, Sarepta is developing a new protocol for Elevidys administration in non-ambulatory patients and plans to submit findings to the FDA [9] Strategic Restructuring - Last month, Sarepta initiated a restructuring plan aimed at saving nearly $400 million annually starting in 2026, which includes laying off 36% of its workforce [10] - The company is now focusing on its siRNA pipeline acquired from Arrowhead Pharmaceuticals as part of its strategic shift [10]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1]. Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [1]. - Specific allegations include that ELEVIDYS posed significant safety risks to patients, trial protocols failed to detect severe side effects, and the severity of adverse events would lead to a halt in recruitment and dosing in trials, attracting regulatory scrutiny [1]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a gene therapy for Duchenne muscular dystrophy [3]. Specific Allegations - The complaint claims that: - ELEVIDYS posed significant safety risks to patients [3]. - Trial regimes and protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment would lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for positive claims about the therapy [3]. Shareholder Actions - Shareholders are encouraged to register for the class action by August 25, 2025, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to lead the case [2]. Group 2: Product and Safety Claims - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its primary product for Duchenne muscular dystrophy [3]. - The company allegedly misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it has been linked to fatal acute liver failure in some patients [3]. Group 3: Stock Price Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock fell by $27.81, or over 27%, from $101.35 to $73.54 [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to drop by more than 40% on July 18, 2025 [5].

Core Viewpoint - Sarepta Therapeutics has faced significant challenges in 2025, with a dramatic decline in share value due to patient deaths linked to its FDA-approved gene therapy, ELEVIDYS, despite generating over $1 billion in revenue since its approval in June 2023 [1][2]. Financial Performance - As of August 11, 2025, Sarepta's shares have dropped over 85% this year, with a market capitalization falling from approximately $11.61 billion to $1.75 billion [2][6]. - The company reported that 54% of its net product revenue in fiscal 2024 came from products other than ELEVIDYS, indicating diversified revenue streams [7]. FDA Interactions - The FDA initially requested Sarepta to halt shipments of ELEVIDYS after multiple patient deaths were reported, leading to a 36% drop in share price [3]. - Following an investigation, the FDA reversed its request, allowing Sarepta to resume sales to ambulatory patients, who represent 70% to 85% of ELEVIDYS patients [4]. Market Sentiment and Analyst Predictions - Following the FDA's reversal, Sarepta's shares increased by 50% as of August 11, reflecting improved market sentiment [5]. - Analysts from Wells Fargo and BMO Capital Markets have set price targets of $50, suggesting a potential upside of around 179% from the current share price [2]. Valuation Metrics - Sarepta's stock is currently trading at a forward price-to-sales (P/S) ratio of 1.2x, significantly lower than the median P/S ratio of 4.3x among U.S. large-cap pharma and biotech stocks, indicating it may be undervalued [7]. Competitive Landscape - Sarepta faces competition from other companies developing DMD therapies, such as Solid Biosciences, which has a treatment in early-stage trials that may mitigate some risks associated with ELEVIDYS [10][11].

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - Investors have until August 25, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Sarepta - Sarepta is accused of making materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with a positive revenue outlook [3]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to recruitment halts and regulatory scrutiny [3]. Group 3: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock fell by $27.81 (27.44%) to close at $73.54 [4]. - After the announcement on April 4, 2025, regarding regulatory scrutiny, the stock dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, led to a further decline of $15.24 (42.12%) to close at $20.91 [4]. - The FDA's Safety Communication on June 24, 2025, resulted in a stock price decrease of $1.52 (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential regulatory scrutiny and risks regarding the therapy's approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1]. Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [1]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to a halt in recruitment and dosing, attracting regulatory scrutiny [1]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action, with a deadline of August 25, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [3].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. Product Safety Concerns - Sarepta allegedly misrepresented the safety profile of Elevidys, claiming that its benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third death related to Elevidys was reported on July 17, 2025, causing the stock to fall by more than 40% on July 18, 2025 [5].